脉心康胶囊防治颈动脉粥样硬化的临床研究  

Clinical Study of Maixinkang Capsule on Preventing and Treating Carotid Atherosclerosis

作　　者：郑广娟[1] 张文高[1] 蔚青[1] 殷镜海[2] 刘龙涛[1] 王大智 王显刚[1] 

机构地区：[1]山东中医药大学 [2]山东中医药大学附属医院 [3]济南炼油厂职工医院

出　　处：《中西医结合心脑血管病杂志》2005年第1期6-7,共2页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

基　　金：山东省自然基金课题 (No.Y2 0 0 1C1 4 )

摘　　要：目的　观察脉心康胶囊对颈动脉粥样硬化治疗的临床疗效。方法　 3 0例颈动脉粥样硬化病人 ,随机分为脉心康组与洛伐他汀组各15例。另外 15例颈动脉粥样硬化病人作为空白对照组。观察用药 6个月后对临床症状的影响 ,用彩色超声多普勒检测颈动脉内膜 -中膜厚度 (IMT)和斑块积分的变化。结果　两治疗组临床症状总疗效、总有效率无统计学意义 ,脉心康组显效率 (73 .3 3 % )明显优于洛伐他汀组 (2 6.67% )。两治疗组治疗后IMT与斑块积分均显著改善 ,两组间比较均无统计学意义 ;两治疗组对颈动脉粥样硬化的控制显效率、总有效率优于空白组。结论　脉心康胶囊与洛伐他汀均具有减轻和消退颈动脉粥样硬化的作用。Objective To observe the clinical effect of maixinkang capsule on carotid atherosclerosis.Methods 30 carotid atherosclerotic patients were randomized into two groups:maixinkang group and lovastatin group. 15 carotid atherosclerotic patients were in the control group. To observe the effect on clinical symptoms. To take an IMT and changes of plaque integral with color ultrasonic doppler.Results There were no difference between two treatment groups in total clinical effects.The significant effective rate in maixinkang group(73.33%) was superior to lovastatin group(26.67%) significantly.IMT and plaque integral reduced significantly in both treatment groups after treatment (six months) and there was no difference between them. The controlled significant effective rate and total effective rate in treatment groups were superior to control group.Conclusion Maixinkang capsule and lovastatin can both alleviate and resolute carotid atherosclerosis.

关 键 词：脉心康胶囊 洛伐他汀 颈动脉粥样硬化 

分 类 号：R543[医药卫生—心血管疾病]